TAIPEI, Taiwan – China's fast-growing health care sector presents excellent opportunities for industry collaboration for overseas companies. And Taiwan, with its existing cultural, language and business ties with China, is particularly well placed to take advantage of those conditions.
HONG KONG – Newly listed Chinese biopharmaceutical company Shenyang-based 3SBio Inc. acquired small-molecule maker Zhejiang Wansheng Pharmaceutical Co. Ltd. for ¥528 million (US$85 million) to complement its oncology and nephrology pipeline.
Lorati Co. Ltd., of Taipei, Taiwan, said it has developed a nano-medication that can effectively inhibit HIV-1 viral replication. The company said the nano-medication, based on bentonite, can yield improvement within one month of treatment.
SHANGHAI – Beijing-based Canbridge Life Sciences Inc. is a biotech that seeks to bring Western innovation to Chinese patients who have few if any treatment options. That licensing strategy has led it to sign a deal with Apogenix GmbH, of Heidelberg, Germany, for lead candidate APG101, an onco-immunotherapy targeting the CD95 ligand for a highly lethal and difficult to treat type of brain cancer, glioblastoma multiforme.
Nanocell firm Engeneic Ltd. started using cancer immunotherapy in its unique way "before anyone else, because we have bacterially derived particles," Managing Director Jennifer MacDiarmid told BioWorld Asia.
SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd., a billion-dollar integrated pharma with R&D centers in New Jersey, Shanghai and Chengdu, has been pushing in the direction of innovation faster and farther than most other Chinese pharmas. And with the recent announcement they will invest ¥850 million (US$137 million) in a biologics manufacturing plant, it's clear the execs aren't afraid to invest heavily in the high-risk area of large molecules and immunotherapy.
SHANGHAI – Phagelux Inc., a Shanghai-based company developing bacteriophages for both human and animal use, has acquired Omnilytics Inc. as part of a mission to leverage phage technology in the battle against antibiotic overuse.
HONG KONG – For five years in a row, China has seen the number of adverse effects from pharmaceuticals rise, but while the numbers are negative at first blush they do point to an improved and much broader monitoring network that has increased the country's pharmacovigilance capability.
SHANGHAI – The Shanghai-based contract research organization/contract manufacturing powerhouse, Wuxi Apptec, is on the move again, this time demonstrating its ability to creatively leverage capital markets to fund expansionary plans.
HONG KONG — An oral cholera vaccine has been shown to be safe and protective against severe disease in children and adults in urban Bangladesh where the disease is endemic, supporting its use in mass immunization programs, according to the first real-life trial of the new Shanchol vaccine.
RSS